DMRA

DAMORA THERAPEUT

• Dow Jones·3d ago

  Damora Therapeutics Initiated at Outperform by RBC Capital

• Dow Jones·3d ago

  Damora Therapeutics Price Target Announced at $40.00/Share by RBC Capital

• Benzinga·3d ago

  RBC Capital Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $40

• TipRanks·4d ago

  Damora Therapeutics initiated with an Outperform at RBC Capital

• PUBT·04/20 20:01

  Damora Therapeutics replaces EY Denmark with EY US as auditor

• Reuters·04/01 21:25

  Damora Therapeutics files Form 3 for CEO, Director Jennifer Jarrett

• Reuters·03/30 12:12

  Damora grants CEO Jennifer Jarrett 1.5 million stock options, 500,000 RSUs as inducement award

• Reuters·03/30 12:00

  DAMORA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

• Reuters·03/25 21:53

  Damora Therapeutics files initial beneficial ownership statement; director Turtle Cameron reports no securities beneficially owned

• Reuters·03/25 21:50

  Damora Therapeutics files initial beneficial ownership statement; director Michael Landsittel reports no securities beneficially owned

• Benzinga·03/25 19:51

  This Vertiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

• Dow Jones·03/25 17:15

  Damora Therapeutics Price Target Announced at $46.00/Share by Evercore ISI Group

• Benzinga·03/25 17:05

  Evercore ISI Group Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $46

• TipRanks·03/25 13:21

  Damora Therapeutics initiated with an Outperform at Evercore ISI

• TipRanks·03/23 13:45

  Damora Therapeutics Announces Major Leadership and Board Overhaul